Compare SRI & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRI | IMUX |
|---|---|---|
| Founded | 1965 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.7M | 152.6M |
| IPO Year | 1997 | 2013 |
| Metric | SRI | IMUX |
|---|---|---|
| Price | $6.85 | $9.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $16.00 | ★ $36.00 |
| AVG Volume (30 Days) | 205.4K | ★ 2.4M |
| Earning Date | 05-01-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $824,444,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.73 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 18.46 | N/A |
| 52 Week Low | $4.16 | $0.51 |
| 52 Week High | $9.71 | $10.91 |
| Indicator | SRI | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 58.44 | 85.13 |
| Support Level | $6.61 | $0.75 |
| Resistance Level | $7.45 | N/A |
| Average True Range (ATR) | 0.45 | 0.46 |
| MACD | 0.07 | 1.01 |
| Stochastic Oscillator | 69.04 | 87.07 |
Stoneridge Inc is a manufacturer of electrical and electronic components used in automotive vehicles. The company produces instrumentation systems, vehicle management electronics, application-specific switches and actuators, sensors, security alarms, and vehicle tracking devices and monitoring services for commercial, automotive, off-highway, and agricultural vehicle markets. The company has three reportable segments: Control Devices, Electronics, and Stoneridge Brazil. It generates the majority of its revenue from the Electronics segment that produces driver information systems, camera-based vision systems, connectivity, and compliance products, and electronic control units. Its geographic segments include America, South America, Europe and Other.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.